Anthera Pharmaceuticals, Inc. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/eca3fb84-5163-448f-aa1f-4a56dcc72494/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2017 | $-36.4M | 2017-01-01 – 2017-12-31 | evidence 0001214659-18-001789 |
| FY 2016 | $-57.2M | 2016-01-01 – 2016-12-31 | evidence 0001214659-17-002018 |
| FY 2015 | $-35.2M | 2015-01-01 – 2015-12-31 | evidence 0001214659-16-010295 |
| FY 2014 | $-28.5M | 2014-01-01 – 2014-12-31 | evidence 0001214659-15-002302 |
| FY 2013 | $-281.9M | 2004-09-10 – 2014-03-31 | evidence 0001214659-14-003584 |
| FY 2012 | $-253.0M | 2004-09-09 – 2013-03-31 | evidence 0001214659-13-002660 |
| FY 2011 | $-210.2M | 2004-09-09 – 2012-03-31 | evidence 0001104659-12-033177 |
| FY 2010 | $-35.8M | 2010-01-01 – 2010-12-31 | evidence 0001047469-12-002644 |
| FY 2009 | $-11.8M | 2009-01-01 – 2009-12-31 | evidence 0001047469-12-002644 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).